Literature DB >> 16284571

Homologous transplantation of neural stem cells to the injured spinal cord of mice.

Roberto Pallini1, Lucia Ricci Vitiani, Alessandra Bez, Patrizia Casalbore, Francesco Facchiano, Valeria Di Giorgi Gerevini, Maria Laura Falchetti, Eduardo Fernandez, Giulio Maira, Cesare Peschle, Eugenio Parati.   

Abstract

OBJECTIVE: Murine neural stem cells (NSCs) were homografted onto the injured spinal cord (SC) to assess their potential to improve motor behavior, to differentiate as neurons, and to establish synapse-like contacts with the descending axonal paths of the host. In addition, we investigated whether transduced NSCs over-expressing vascular endothelial growth factor might exert any angiogenetic effect in the injured SC.
METHODS: NSCs derived from mouse embryos were transduced to express either green fluorescent protein or vascular endothelial growth factor. The cells were engrafted in mice where an extended dorsal funiculotomy had been performed at the T8-T9 level. At intervals from 4 to 12 weeks after grafting, motor behavior was assessed using an open field locomotor scale and footprint analysis. At the same time points, the SC was studied by conventional histology, immunohistochemistry, and fluorescence microscopy. The interactions between the grafted NSCs and descending axonal paths were investigated using anterogradely transported fluorescent axonal tracers.
RESULTS: By the 12-week time point, mice engrafted with NSCs significantly improved both their locomotor score on open field test and their base of support on footprint analysis. Histological studies showed that green fluorescent protein-positive NSCs survived as long as 12 weeks after grafting, migrated from the grafting site with a tropism toward the lesion, and either remained undifferentiated or differentiated into the astrocytic phenotype without neuronal or oligodendrocytic differentiation. Interestingly, the NSC-derived astrocytes expressed vimentin, suggesting that these cells differentiated as immature astrocytes. The tips of severed descending axonal paths came adjacent to grafted NSCs without forming synapse-like structures. When genetically engineered to over-express vascular endothelial growth factor, the grafted NSCs significantly increased vessel density in the injured area.
CONCLUSION: In the traumatically injured mice SC, NSC grafting improves motor recovery. Although differentiation of engrafted NSCs is restricted exclusively toward the astrocytic phenotype, the NSC-derived astrocytes show features that are typical of the early phase after SC injury when the glial scar is still permissive to regenerating axons. The immature phenotype of the NSC-derived astrocytes suggests that these cells might support neurite outgrowth by the host neurons. Thus, modifying the glial scar with NSCs might enhance axonal regeneration in the injured area. The use of genetically engineered NSCs that express trophic factors appears to be an attractive tool in SC transplantation research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284571     DOI: 10.1227/01.neu.0000180058.58372.4c

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  33 in total

1.  Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord.

Authors:  Thais Federici; Jonathan Riley; John Park; Mark Bain; Nicholas Boulis
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

Review 2.  Don't fence me in: harnessing the beneficial roles of astrocytes for spinal cord repair.

Authors:  Robin E White; Lyn B Jakeman
Journal:  Restor Neurol Neurosci       Date:  2008       Impact factor: 2.406

Review 3.  Current challenges for the advancement of neural stem cell biology and transplantation research.

Authors:  Kristien Reekmans; Jelle Praet; Jasmijn Daans; Veerle Reumers; Patrick Pauwels; Annemie Van der Linden; Zwi N Berneman; Peter Ponsaerts
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

4.  Effect of hyperbaric oxygen on MMP9/2 expression and motor function in rats with spinal cord injury.

Authors:  Ying-Nuo Hou; Wen-Yuan Ding; Yong Shen; Da-Long Yang; Lin-Feng Wang; Peng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Laser injury promotes migration and integration of retinal progenitor cells into host retina.

Authors:  Caihui Jiang; Henry Klassen; Xinmei Zhang; Michael Young
Journal:  Mol Vis       Date:  2010-06-04       Impact factor: 2.367

Review 6.  Olfactory ensheathing cells promote differentiation of neural stem cells and robust neurite extension.

Authors:  Rosh Sethi; Roshan Sethi; Andy Redmond; Erin Lavik
Journal:  Stem Cell Rev Rep       Date:  2014-12       Impact factor: 5.739

7.  Gene expression profiling of human neural progenitor cells following the serum-induced astrocyte differentiation.

Authors:  Shinya Obayashi; Hiroko Tabunoki; Seung U Kim; Jun-ichi Satoh
Journal:  Cell Mol Neurobiol       Date:  2009-01-07       Impact factor: 5.046

8.  Assessment of Neuroprotective Effects of Local Administration of 17- Beta- Estradiol on Peripheral Nerve Regeneration in Ovariectomized Female Rats.

Authors:  Ahmadreza Nobakhti-Afshar; Alireza Najafpour; Rahim Mohammadi; Leila Zarei
Journal:  Bull Emerg Trauma       Date:  2016-07

9.  Engineering angiogenesis following spinal cord injury: a coculture of neural progenitor and endothelial cells in a degradable polymer implant leads to an increase in vessel density and formation of the blood-spinal cord barrier.

Authors:  Millicent Ford Rauch; Sara Royce Hynes; James Bertram; Andy Redmond; Rebecca Robinson; Cicely Williams; Hao Xu; Joseph A Madri; Erin B Lavik
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

10.  Therapeutic potential of human olfactory bulb neural stem cells for spinal cord injury in rats.

Authors:  H E Marei; A Althani; S Rezk; A Farag; S Lashen; N Afifi; A Abd-Elmaksoud; R Pallini; P Casalbore; C Cenciarelli; T Caceci
Journal:  Spinal Cord       Date:  2016-02-16       Impact factor: 2.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.